1. bookVolume 3 (2020): Edition 1 (June 2020)
Détails du magazine
License
Format
Magazine
eISSN
2668-5124
Première parution
30 Sep 2019
Périodicité
2 fois par an
Langues
Anglais
Accès libre

COVID-19: A Centennial Pandemic from Origin to Clinical Trials

Publié en ligne: 29 Jun 2020
Volume & Edition: Volume 3 (2020) - Edition 1 (June 2020)
Pages: 30 - 52
Reçu: 18 May 2020
Accepté: 10 Jun 2020
Détails du magazine
License
Format
Magazine
eISSN
2668-5124
Première parution
30 Sep 2019
Périodicité
2 fois par an
Langues
Anglais

1. Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, Makhawi AM (2020) Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach. BioRxiv 2020.02.04.934232. doi: 10.1101/2020.02.04.93423210.1101/2020.02.04.934232Search in Google Scholar

2. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9:e00221-18. doi: 10.1128/mBio.00221-1810.1128/mBio.00221-18584499929511076Search in Google Scholar

3. Albarello F, Pianura E, Di SF, Cristofaro M, Petrone A, Marchioni L, Palazzolo C, Schininà V, Nicastri E, Petrosillo N, Campioni P, Eskild P, Zumla A, Ippolito G, Abbonizio MA, Agrati C, Amadei G, Amendola A, Antonini M, Barbaro R, Bartolini B, Benigni M, Bevilacqua N, Bordi L, Bordoni V, Branca M, Capobianchi MR, Caporale C, Caravella I, Carletti F, Castilletti C, Chiappini R, Ciaralli C, Colavita F, Corpolongo A, Curiale S, D’Abramo A, Dantimi C, Angelis AD, Angelis GD, Lorenzo RD, Stefano FD, Ferraro F, Fiorentini L, Frustaci A, Gallì P, Garotto G, Giancola ML, Giansante F, Giombini E, Greci MC, Lalle E, Lanini S, Lapa D, Lepore L, Lucia A, Lufrani F, Macchione M, Marani A, Mariano A, Marini MC, Maritti M, Matusali G, Meschi S, Montaldo FMC, Murachelli S, Noto R, Pallini E, Passeri V, Pelliccioni F, Petrecchia A, Pisciotta M, Pittalis S, Proietti C, Puro V, Rinonapoli G, Rueca M, Sacchi A, Sanasi F, Santagata C, Scarcia S, Scognamiglio P, Scorzolini L, Stazi G, Vaia F, Vairo F, Valli MB (2020) 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation. Int J Infect Dis 93:192–197. doi: 10.1016/j.ijid.2020.02.043.10.1016/j.ijid.2020.02.043711043632112966Search in Google Scholar

4. Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, Housa A, Almazro MA, Alraihan N, Banjar A, Albalawi E, Alhindi H, Choudhry AJ, Meiman JG, Paczkowski M, Curns A, Mounts A, Feikin DR, Marano N, Swerdlow DL, Gerber SI, Hajjeh R, Madani TA (2016) Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 22:49–55. doi: 10.3201/eid2201.15134010.3201/eid2201.151340469671426692185Search in Google Scholar

5. Aylward, Bruce (WHO), Liang W (PRC) (2020) Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). In- The WHO-China Joint Mission on Coronavirus Disease 2019, 2019(February):16–24. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed 05 April 2020Search in Google Scholar

6. Boktor SW, Hafner JW (2020) Influenza. In: StatPearls. Treasure Island (FL). StatPearls Publishing. PMID: 29083802Search in Google Scholar

7. Casadevall A, Pirofski L (2020) The convalescent sera option for containing COVID-19. J Clin Invest 130:1545–1548. doi: 10.1172/jci13800310.1172/JCI138003710892232167489Search in Google Scholar

8. Centers for Disease Control and Prevention (2020) CDC Laboratory Testing for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Serology Tests. http://www.cdc.gov/coronavirus/mers/lab/lab-testing.html. Accessed 05 April 2020Search in Google Scholar

9. Chen Y, Liu Q, Guo D (2020) Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 92:418–423. doi: 10.1002/jmv.2568110.1002/jmv.25681716704931967327Search in Google Scholar

10. Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, Chan P, Wong KC, Leung CB, Cheng G (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44–46. doi: 10.1007/s10096-004-1271-910.1007/s10096-004-1271-9708835515616839Search in Google Scholar

11. Cherry JD (2004) The chronology of the 2002-2003 SARS mini pandemic. Paediatr Respir Rev 5:262–269. doi: 10.1016/j.prrv.2004.07.00910.1016/j.prrv.2004.07.009710608515531249Search in Google Scholar

12. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Kao RYT, Poon LLM, Wong CLP, Guan Y, Peiris JS M, Yuen KY (2004) Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 59:252–256. doi: 10.1136/thorax.2003.01265810.1136/thorax.2003.012658174698014985565Search in Google Scholar

13. Corman VM, Muth D, Niemeyer D, Drosten C (2018) Hosts and Sources of Endemic Human Coronaviruses. Adv Virus Res 100:163-188. doi: 10.1016/bs.aivir.2018.01.00110.1016/bs.aivir.2018.01.001711209029551135Search in Google Scholar

14. Sobi (2020) Sobi ’ s Anakinra & Emapalumab Requested for Use in Targeted Clinical Study in Italy to Address Severe COVID-19 Cases. In: TrialSiteNews. https://www.trialsitenews.com/sobisanakinra-emapalumab-requested-for-usein-targeted-clinical-study-in-italy-to-address-severe-covid-19-cases/Accessed 05 April 2020.Search in Google Scholar

15. Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192. doi: 10.1038/s41579-018-0118-910.1038/s41579-018-0118-9Search in Google Scholar

16. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G (2020) Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 12:372. doi: 10.3390/v1204037210.3390/v12040372Search in Google Scholar

17. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, Feng J, Yang D, Gao G, Jin G (2005) A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun 333:186-193. doi: 10.1016/j.bbrc.2005.05.08910.1016/j.bbrc.2005.05.089Search in Google Scholar

18. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, Ntaganou M (2020) Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe 27:992-1000.e3. doi: 10.1016/j.chom.2020.04.00910.1016/j.chom.2020.04.009Search in Google Scholar

19. Fan C, Li K, Ding Y, Lu WL, Wang J (2020) ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection. MedRxiv 2020.02.12.20022418. doi: 10.1101/2020.02.12.2002241810.1101/2020.02.12.20022418Search in Google Scholar

20. Fox RI (1993) Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheu 23:82–91. doi: 10.1016/S0049-0172(10)80012-510.1016/S0049-0172(10)80012-5Search in Google Scholar

21. Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B 93:449-463. https://doi.org/10.2183/pjab.93.02710.2183/pjab.93.027571317528769016Search in Google Scholar

22. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B, Zhang W, Peng C, Zhang YJ, Luo CM, Tan B, Wang N, Zhu Y, Crameri G, Zhang SY, Wang L F, Daszak P, Shi ZL (2013) Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503:535–538. doi: 10.1038/nature1271110.1038/nature12711538986424172901Search in Google Scholar

23. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D, Perlman S, Poon LM, Samborskiy DV, Sidorov IA, Sola I, Ziebuhr J (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544. doi: 10.1038/s41564-020-0695-z10.1038/s41564-020-0695-z709544832123347Search in Google Scholar

24. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros RE, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D’Arminio MA, Ismail S, Kato H, Lapadula G, L’Her E, Maeno T, Majumder S, Massari M, Mora RM, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T (2020) Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 382:2327-2336. doi: 10.1056/NEJMoa200701610.1056/NEJMoa2007016716947632275812Search in Google Scholar

25. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Med Res 7:11. doi: 10.1186/s40779-020-00240-010.1186/s40779-020-00240-0Search in Google Scholar

26. Gyawali B, Ramakrishna K, Dhamoon AS (2019) Sepsis: The evolution in definition, pathophysiology, and management. SAGE Open Med 7:1-13 doi: 10.1177/205031211983504310.1177/2050312119835043Search in Google Scholar

27. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, Van GH (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631–637. doi: 10.1002/path.157010.1002/path.1570Search in Google Scholar

28. Harrison C (2020) Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 38:379–381. doi: 10.1038/d41587-020-00003-110.1038/d41587-020-00003-1Search in Google Scholar

29. Healy M (2020) How a discovery that brought us Viagra could help those battling the coronavirus. In: Bangor Daily News, LA. https://www.healthleadersmedia.com/innovation/how-discovery-brought-us-viagra-could-help-those-battling-coronavirus. Accessed 06 April 2020Search in Google Scholar

30. Hodgson J (2020) The pandemic pipeline. Nat Biotechnol 38:523-532. doi: 10.1038/d41587-020-00005-z10.1038/d41587-020-00005-zSearch in Google Scholar

31. Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Böddinghaus B, Götsch U, Naujoks F, Neumann P, Schork J, Tiarks-Jungk P, Walczok A, Eickmann M, Vehreschild M, Kann G, Wolf T, Gottschalk R, Ciesek S (2020) Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med 382:1278–1280. doi: 10.1056/NEJMc200189910.1056/NEJMc2001899Search in Google Scholar

32. Hongyi C, Zhicheng Z, Li W, Zhihua H, Fanghua G, Xiaodong L, Yahong C, Jinzi JW (2020) First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients Hongyi. MedRxiv 2020.03.22.20034041. doi: 10.1101/2020.03.22.2003404110.1101/2020.03.22.20034041Search in Google Scholar

33. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL (2016) Sepsis and septic shock. Nat Rev Dis Primers 2:1-21. doi: 10.1038/nrdp.2016.4510.1038/nrdp.2016.45Search in Google Scholar

34. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. doi: 10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5Search in Google Scholar

35. Hussain S, Pan J, Chen Y, Yang Y, Xu J, Peng Y, Wu Y, Li Z, Zhu Y, Tien P, Guo D (2005) Identification of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus. J Virol 79:5288–5295. doi: 10.1128/jvi.79.9.5288-5295.200510.1128/JVI.79.9.5288-5295.2005108277215827143Search in Google Scholar

36. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC (2016) Combination therapy with lopinavir/ritonavir, ribavirin and interferona for Middle East respiratory syndrome. Antivir Ther 2:455–459. doi: 10.3851/IMP300210.3851/IMP3002Search in Google Scholar

37. Lam TTY, Shum MHH, Zhu HC, Tong YG, Ni XB, Liao YS, Wei W, Cheung WYM, Li WJ, Li LF, Leung GM, Holmes EC, Hu YL, Guan Y (2020) Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 1-4. doi: 10.1038/s41586-020-2169-010.1038/s41586-020-2169-0Search in Google Scholar

38. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581:215-220. doi: 10.1038/s41586-020-2180-510.1038/s41586-020-2180-5Search in Google Scholar

39. Lankadasari MB, Aparna JS, Mohammed S, James S, Aoki K, Binu VS, Nair S, Harikumar KB (2018) Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. Theranostics 8:3824-3840. doi: 10.7150/thno.2530810.7150/thno.25308Search in Google Scholar

40. Lau SKP, Woo PCY, Li KSM, Huang Y, Tsoi HW, Wong BHL, Wong SSY, Leung SY, Chan KH, Yuen KY (2005) Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 102:14040–14045. doi: 10.1073/pnas.050673510210.1073/pnas.0506735102Search in Google Scholar

41. Liao J, Fan S, Chen J, Wu J, Xu S, Guo Y, Li C, Zhang X, Wu C, Mou H, Song C, Li F, Wu G, Zhang J, Guo L, Liu H, Lv J, Xu L, Lang C (2020) Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. MedRxiv 2020.03.10.20032136. doi: 10.1101/2020.03.10.2003213610.1101/2020.03.10.20032136Search in Google Scholar

42. Lounder DT, Bin Q, De MC, Jordan MB (2019) Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv 3:47–50. doi: 10.1182/bloodadvances.201802585810.1182/bloodadvances.2018025858Search in Google Scholar

43. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565–574. doi: 10.1016/S0140-6736(20)30251-810.1016/S0140-6736(20)30251-8Search in Google Scholar

44. Lythgoe MP, Middleton P (2020) Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends in Pharmacological Sci 41:363-382. doi: 10.1016/j.tips.2020.03.00610.1016/j.tips.2020.03.006714466532291112Search in Google Scholar

45. Madjid M, Lillibridge S, Mirhaji P, Casscells W (2020) Influenza as a bioweapon. J R Soc Med 96:345–346. doi: 10.1177/01410768030960070910.1177/014107680309600709Search in Google Scholar

46. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395:1033–1034. doi: 10.1016/S0140-6736(20)30628-010.1016/S0140-6736(20)30628-0Search in Google Scholar

47. Mei X, Lee HC, Diao KY, Huang M, Lin B, Liu C, Xie Z, Ma Y, Robson PM, Chung M, Bernheim A, Mani V, Calcagno C, Li K, Li S, Shan H, Lv J, Zhao T, Xia J, Long Q, Steinberger S, Jacobi A, Deyer T, Luksza M, Liu F, Little BP, Fayad ZA, Yang Y (2020) Artificial intelligence-enabled rapid diagnosis of patients with COVID-19. Nat Med 1-5. doi: 10.1038/s41591-020-0931-310.1038/s41591-020-0931-3744672932427924Search in Google Scholar

48. Mishra S, Carnahan R (2020) Coronavirus : A new type of vaccine using RNA could help defeat COVID-19. 2, 1–5, Australia. In: The Conversation Blog. https://theconversation.com/coronavirus-anew-type-of-vaccine-using-rna-could-help-defeat-covid-19-133217. Accessed 06 May 2020Search in Google Scholar

49. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J (2005) Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Bioph Res Co 326:905-908. doi: 10.1016/j.bbrc.2004.11.12810.1016/j.bbrc.2004.11.128709285115607755Search in Google Scholar

50. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, Kellner MJ, Tan AL, Paul LM, Parham LA, Garcia KF, Barnes KG, Chak B, Mondini A, Nogueira ML, Isern S, Michael SF, Lorenzana I, Yozwiak NL, MacInnis BL, Bosch I, Gehrke L, Zhang F, Sabeti PC (2018) Field-deployable viral diagnostics using CRISPR-Cas13. Science, 360:444–448. doi: 10.1126/science.aas883610.1126/science.aas8836619705629700266Search in Google Scholar

51. Pan L, Mu M, Ren HG, Yang P (2020) Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 115:766-773. doi: 10.14309/ajg.000000000000062010.14309/ajg.0000000000000620717249232287140Search in Google Scholar

52. Perlman S, Netland J (2009) Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol 7:439–450. doi:10.1038/nrmicro214710.1038/nrmicro2147283009519430490Search in Google Scholar

53. Peroni JF, Borjesson DL (2011) Anti-Inflammatory and Immunomodulatory Activities of Stem Cells. Veterinary Clinics of North America - Equine Practice 27:351–362. doi: 10.1016/j.cveq.2011.06.00310.1016/j.cveq.2011.06.00321872763Search in Google Scholar

54. Su H, Yang M, Wan C, Yi L, Tang F, Zhu H, Yi F, Yang H, Fogo AB, Nie X, Zhang C (2020) Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 1-9. doi: 10.1016/j.kint.2020.04.00310.1016/j.kint.2020.04.003719410532327202Search in Google Scholar

55. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L (2020) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17:613–620. doi:10.1038/s41423-020-0400-410.1038/s41423-020-0400-4709188832203189Search in Google Scholar

56. Tang X, Wu CLX, Song Y, Yao X, Wu X, Dung Y, Zhang H, Wang Y, Qian Z, Cui J, Lu J (2020b) On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev nwaa036. doi: 10.1093/nsr/nwaa03610.1093/nsr/nwaa036710787534676127Search in Google Scholar

57. Tetro JA (2020) Is COVID-19 receiving ADE from other coronaviruses? Microbe Infect 22:72–73. doi: 10.1016/j.micinf.2020.02.00610.1016/j.micinf.2020.02.006710255132092539Search in Google Scholar

58. Triana-Baltzer GB, Gubareva LV, Nicholls JM, Pearce MB, Mishin VP, Belser JA, Chen LM, Chan RWY, Chan MCW, Hedlund M, Larson JL, Moss RB, Katz JM, Tumpey TM, Fang F (2009) Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 4:12–14. doi: 10.1371/journal.pone.000778810.1371/journal.pone.0007788277064019893747Search in Google Scholar

59. Van DN, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO (2020) Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 382:1564-1567. doi: 10.1056/NEJMc200497310.1056/NEJMc2004973712165832182409Search in Google Scholar

60. Vijaykrishna D, Smith GJD, Zhang JX, Peiris JSM, Chen H, Guan Y (2007) Evolutionary Insights into the Ecology of Coronaviruses. J Virol 81:4012–4020. doi: 10.1128/jvi.02605-0610.1128/JVI.02605-06186612417267506Search in Google Scholar

61. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323:1061–1069. doi: 10.1001/jama.2020.158510.1001/jama.2020.1585704288132031570Search in Google Scholar

62. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271. doi: 10.1038/s41422-020-0282-010.1038/s41422-020-0282-0705440832020029Search in Google Scholar

63. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W (2020) Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 323:1843–1844. doi: 10.1001/jama.2020.378610.1001/jama.2020.3786706652132159775Search in Google Scholar

64. Wenzel RP, Edmond MB (2003) Managing SARS amidst uncertainty. N Engl J Med 348:1947–1948. doi: 10.1056/NEJMp03007210.1056/NEJMp03007212748313Search in Google Scholar

65. WHO (2020) Emergencies preparedness, response. Pneumonia of unknown origin – China. Disease outbreak news. In: WHO Website. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Accessed 06 April 2020Search in Google Scholar

66. Wit ED, Doremalen NV, Falzarano D, Munster VJ (2016). REVIEWS SARS and MERS : recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534. doi: 10.1038/nrmicro.2016.8110.1038/nrmicro.2016.81709782227344959Search in Google Scholar

67. Worldometer Corona (2020) COVID-19 CORONAVIRUS PANDEMIC. In: Worldometer Corona https://www.worldometers.info/coronaviru/ Accessed 09 June 2020Search in Google Scholar

68. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jiang T (2020) Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 27:325–328. doi: 10.1016/j.chom.2020.02.00110.1016/j.chom.2020.02.001715451432035028Search in Google Scholar

69. Wu F, Zhao S, Yu B, Chen YM, Wang W, Hu Y, Song ZG, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ (2020) Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. BioRxiv 2020.01.24.919183. doi: 10.1101/2020.01.24.91918310.1101/2020.01.24.919183Search in Google Scholar

70. Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239-42. doi: 10.1001/jama.2020.264810.1001/jama.2020.264832091533Search in Google Scholar

71. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L (2020) Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 1-3. doi: 10.1038/s41423-020-0374-210.1038/s41423-020-0374-2707527832047258Search in Google Scholar

72. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H (2020) Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 158:1831-1833. doi: 10.1053/j.gastro.2020.02.05510.1053/j.gastro.2020.02.055713018132142773Search in Google Scholar

73. Xie L, Sun C, Luo C, Zhang Y, Zhang J, Yang J, Chen L, Yang J, Li J (2020) SARSCoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development. BioRxiv 2020.02.16.951723. doi: 10.1101/2020.02.16.95172310.1101/2020.02.16.951723Search in Google Scholar

74. Xiong C, Jiang L, Chen Y, Jiang Q (2020) Evolution and variation of 2019-novel coronavirus. BioRxiv 2020.01.30.926477. doi: org/10.1101/2020.01.30.92647710.1101/2020.01.30.926477Search in Google Scholar

75. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N (2004) HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Bioph Res Co 318:719-25. doi: 10.1016/j.bbrc.2004.04.08310.1016/j.bbrc.2004.04.083711100515144898Search in Google Scholar

76. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Liu D, Clinical D, Liu D, Tan W Liu D (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point : Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis 2:1–25. doi: 10.1093/cid/ciaa23710.1093/cid/ciaa237710813032150618Search in Google Scholar

77. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. doi: 10.1038/s41586-020-2012-710.1038/s41586-020-2012-7709541832015507Search in Google Scholar

78. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733. doi: 10.1056/NEJMoa200101710.1056/NEJMoa2001017709280331978945Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo